Skip Navigation
medication-assisted treatment for substance use disorders

What's New

2014

  • Information about potential risks of marijuana use. Posted September 2014
    This letter provides information about potential risks associated with marijuana use in patients being treated for opioid use disorders with medication assisted treatments such as methadone, buprenorphine, and naltrexone.
  • Expansion of naloxone in the prevention of opioid overdose FAQs. Posted July 2014
    SAMHSA's answers to frequently asked questions about expansion of naloxone in the prevention of opioid overdose.
  • PIPMAG "Standards of Care" released. Posted April 2014
    A document of great interest to physicians providing care for patients with addiction was released on February 20, 2014, by the American Society of Addiction Medicine (ASAM). “Standards of Care: for the Addiction Specialist Physician” (The Standards) is the first in a series of reports being produced by the Practice Improvement and Performance Measurement Action Group (PIPMAG) convened by ASAM with support from the SAMHSA, and overseen by representatives of other professional societies as well as the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism.
  • Important documents to reduce the risk of opioid overdose. Posted April 2014
    The Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Treatment is pleased to announce the release of two important documents that are designed to reduce the risk of opioid overdose and death.
  • Guidance for prescribing non-controlled substances. Posted March 2014
    In response to inquiries from the field and in consultation with the U.S. Drug Enforcement Administration (DEA), SAMHSA offers the following guidance regarding the prescribing and dispensing of non-controlled substances in the Opioid Treatment Program (OTPS) setting.
  • The use of buprenorphine for the treatment of opioid addiction in adolescents. Posted March 2014
    The use of buprenorphine for the treatment of opioid addiction in adolescents has not been systematically studied. It is known, however, that patients younger than 18 years of age, with relatively short addiction histories, are at particularly high risk for serious complications of addiction (e.g., overdose deaths, suicide, HIV, other infectious diseases). Many experts in the field of opioid addiction treatment believe that buprenorphine should be the treatment of choice for adolescent patients with short addiction histories.
  • SAMHSA warns about fentanyl. Posted February 2014
    The Substance Abuse and Mental Health Services Administration (SAMHSA) is alerting the treatment community and the general public that since the beginning of the year a marked increase in deaths reportedly linked to the use of heroin contaminated with the drug fentanyl has been noted. Fentanyl is a form of opioid and when used in combination with heroin can rapidly cause severe injury and even death.

2013

  • New Upcoming PCSS-O Webinar on 12/11/2013. Posted December 2013
    Prescribers’ Clinical Support System for Opioid Therapies (PCSS-O) is a three year grant funded by Substance Abuse and Mental Health Services Administration (SAMHSA), and Center for Substance Abuse Treatment (CSAT). It is a collaborative project led by American Academy of Addiction Psychiatry (AAAP) with: American Dental Association (ADA), American Medical Association (AMA), American Osteopathic Academy of Addiction Medicine (AOAAM), American Psychiatric Association (APA), American Society for Pain Management Nursing (ASPMN), and International Nurses Society on Addictions (IntNSA). These organizations provide FREE educational trainings on the safe and effective prescribing of opioid medications in the treatment of pain and/or opioid addiction.
  • Safe methadone induction and stabilization: Report of an expert panel. Posted December 2013
    There is a new article in PubMed by Baxter LE Sr, Campbell A, Deshields M, Levounis P, Martin JA, McNicholas L, Payte JT, Salsitz EA, Taylor T, Wilford BB. "Safe methadone induction and stabilization: Report of an expert panel". J Addict Med. 2013 Nov-Dec;7(6):377-386.
  • CDC announcement regarding deaths and severe adverse reactions associated with AAROD. Posted November 2013
    When compared to standard detoxification with steadily reducing doses of long-acting opioid agonists over a period of 3 to 21 days, AAROD provides neither greater relief of short-term, subjective withdrawal symptoms nor achievement of short-term abstinence. And, the few existing long-term studies indicate that AAROD does not improve rates of abstinence at 12 months when compared with standard detoxification.
  • SAMHSA's new Opioid Overdose Prevention Toolkit. Posted November 2013
    On August 28th SAMHSA released the Opioid Overdose Prevention Toolkit. Treatment providers have the opportunity to deliver important prevention messages and resources, (e.g. naloxone), at times when a person can be most at risk for overdose such as upon completing detoxification, or medically managed withdrawal; completing residential rehabilitation; or upon entering or leaving medication-assisted treatment.
  • Information about the new buprenorphine product from Orexo US. Posted August 2013
    On July 3, 2013, Orexo US became the latest pharmaceutical company to add to the ever growing list of buprenorphine products. Orexo received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv® (buprenorphine and naloxone sublingual tablets). Zubsolv is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Zubsolv is due to be released in September 2013.
  • Information about the appearance of fentanyl analogues. Posted July 2013
    Many of you will remember the period from 2005 through 2007 when illicit fentanyl-laced heroin caused a great number of overdose deaths. That was not the first time illicit fentanyl, also called fentanyl analogues, entered the drug market, and likely will not be the last. Recently, small clusters of overdoses and overdose fatalities in a variety of communities, mostly in the eastern United States, have raised alarm. Little is fully known about the situation but it appears fentanyl analogues are involved in at least some of the cases, and may be contaminating both heroin and cocaine. More information about the current situation has been published by the CDC as a health advisory.
  • Information about the national availability of PPD products. Posted July 2013
    A shortage of tuberculin purified protein derivative (PPD; Tubersol® and Aplisol®) needed for tuberculosis testing began in autumn 2012 when the supply of Tubersol® was interrupted. A shortage of Aplisol® ensued. Although the production of Tubersol® has been restored, the two PPD products might not be available from all suppliers yet.
  • The revised draft of Federal Guidelines for Opioid Treatment. Posted May 2013
    The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT) is seeking public comments on the revised 2007 SAMHSA Guidelines for the Accreditation of Opioid Treatment Programs. These guidelines elaborated upon the Federal opioid treatment standards set forth under 42 CFR Part 8.
    The revised Guidelines for the Accreditation of Opioid Treatment Programs, 2013 (PDF, 982 KB)

2012

  • Prescription Monitoring Program Presentation. Posted December 2012
    The attached presentation on the use of prescription drug monitoring program information in OTP settings is provided for information purposes. By posting, SAMHSA/CSAT is not suggesting that its content and recommendations are SAMHSA/CSAT approved or endorsed.
  • Rule Provides Flexibility in Dispensing Buprenorphine for Opioid Addiction Treatment Posted December 2012
    Today, SAMHSA issued a Federal rule to allow patients being treated through an Opioid Treatment Program (OTP) to receive take-home supplies of buprenorphine from an OTP in a more flexible manner. Buprenorphine is a medication used in opioid addiction treatment. The regulation takes effect on January 7, 2013.
    Under the rule change, OTPs will be permitted to dispense buprenorphine to eligible patients without having to adhere to previous length of time in treatment requirements. Currently, OTPs require a person to be in treatment a certain amount of time before being given a multiple days' supply of medicine to take home.
    The change in the rule will not affect requirements for dispensing methadone—the other opioid agonist treatment medication used by OTPs. SAMHSA based the change in the restrictions for dispensing buprenorphine on several factors. These include differences in the abuse potential between methadone and buprenorphine, as well as the actual abuse and mortality rates (buprenorphine is lower in each instance).
  • National Hepatitis Awareness Month. Posted May 2012
    This letter is a brief reminder that May is National Hepatitis Awareness Month. An estimated 3.5–5.3 million Americans are living with chronic (lifelong) hepatitis B or hepatitis C virus infection. Most of them do not know that they are infected, placing them at greater risk for severe, even fatal, complications from the disease and increasing the likelihood that they will spread the virus to others. We encourage you to use Hepatitis Awareness Month to learn more about this “silent epidemic.”
  • Winners of the 2012 Science to Service Awards. Posted February 2012

2011

2010

2009

2008

2007

2006

PDF File*PDF formatted files require that Adobe Acrobat Reader® program.
Follow this link to download this FREE software now from Adobe.
 
Note to users of screen readers and other assistive technologies: Please report your problems
to us at otp-extranet@opioid.samhsa.gov.
link to the Substance Abuse & Mental Health Services Administration division of pharmacologic therapies logo